Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

PMID:
25758770
2.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

3.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

4.

Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.

Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S; International HypoCCS Advisory Board.

J Clin Endocrinol Metab. 2013 Mar;98(3):980-8. doi: 10.1210/jc.2012-2684. Epub 2013 Jan 23.

5.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

6.

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group.

Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14.

7.

Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.

Ram CV, Sachson R, Littlejohn T, Qian C, Shojaee A, Stoakes KA, Neutel JM.

Am J Cardiol. 2011 May 1;107(9):1346-52. doi: 10.1016/j.amjcard.2010.12.045.

PMID:
21497211
8.
9.

Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects.

Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR; International HypoCCS Advisory Board.

Clin Endocrinol (Oxf). 2010 Jan;72(1):59-69. doi: 10.1111/j.1365-2265.2009.03612.x. Epub 2009 May 4.

PMID:
19438908
10.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

11.

Does treatment with duloxetine for neuropathic pain impact glycemic control?

Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ.

Diabetes Care. 2007 Jan;30(1):21-6.

PMID:
17192327
12.

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group.

Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112.

PMID:
15823767
13.

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia.

Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, Sachson R, Samuel P.

Am J Cardiol. 2000 May 1;85(9):1100-5.

PMID:
10781759
14.

The rationale for treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism. Prednisone therapy v chicken soup.

Dorfman S, Sachson R, Feld S.

Arch Intern Med. 1982 Dec;142(13):2261. No abstract available.

PMID:
7149866
15.

Failure of intrasellar muscle implants to prevent recurrent downward migration of the optic chiasm.

Hudgins WR, Raney LA, Young SW, Sachson RA.

Neurosurgery. 1981 Feb;8(2):231-2. No abstract available.

PMID:
7207790
16.

Letter: Insulin lipoatrophy.

Sachson RA, Feld S.

JAMA. 1976 Aug 16;236(7):820-1. No abstract available.

PMID:
947255
17.

Pituitary stones.

Di Chiro G, Saldino R, McGuffin WL Jr, Sachson RA, Gorden P, Bartter FC.

Ann Intern Med. 1975 Jul;83(1):66-9.

PMID:
1147440
18.

Prolactin stimulation by thyrotropin-releasing hormone in a patient with isolated thyrotropin deficiency.

Sachson R, Rosen SW, Cuatrecasas P, Roth J, Frantz AG.

N Engl J Med. 1972 Nov 9;287(19):972-3. No abstract available.

PMID:
4627862
19.

Porphyria cutanea tarda: role of iron.

Sachson RA.

N Engl J Med. 1969 Feb 13;280(7):387. No abstract available.

PMID:
5762593
20.

THE INDUCTION OF delta-AMINOLEVULINIC ACID SYNTHETASE in vivo IN CHICK EMBRYO LIVER BY NATURAL STEROIDS.

Kappas A, Song CS, Levere RD, Sachson RA, Granick S.

Proc Natl Acad Sci U S A. 1968 Oct;61(2):509-13. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk